We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

This study has been terminated.
(Persantine is no longer being used at UCHC for pharmacological stress testing)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00760708
First Posted: September 26, 2008
Last Update Posted: January 17, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
Bruce Liang, University of Connecticut Health Center
  Purpose
Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. Thus, the purpose of this study is to determine the relationship between the mutation and the transporter function.

Condition
Ischemia Coronary Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

Resource links provided by NLM:


Further study details as provided by Bruce Liang, University of Connecticut Health Center:

Primary Outcome Measures:
  • To determine functional significance and association of these polymorphisms with the ability of persantine to inhibit uridine (uridine uses the same transporter) uptake and platelet aggregation. [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Investigators will study the association of these polymorphisms with any clinical characteristics such as the incidence of MI, acute coronary syndrome, coronary bypass or stenting procedures. These clinical outcomes are considered secondary endpoints. [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA
whole blood

Enrollment: 221
Study Start Date: September 2005
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
undergoing persantine stress test

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects undergoing a Persantine nuclear stress test for medically-indicated reasons. There are no control subjects.
Criteria

Inclusion Criteria:

  • Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test

Exclusion Criteria:

  • Oral persantine use within 24 hours
  • Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
  • Active asthma or bronchospasm
  • Those with end-stage liver disease such as cirrhosis or active hepatitis such as > 5 fold liver enzyme elevation will not be included
  • Anemia (Hct < 30)
  • Myocardial infarction within 30 days
  • Severe left ventricular dysfunction (EF < 30%)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00760708


Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06032
Sponsors and Collaborators
UConn Health
United States Department of Defense
Investigators
Principal Investigator: Bruce T Liang, MD UConn Health
  More Information

Responsible Party: Bruce Liang, Professor of Medicine, Director Pat and Jim Calhoun Cardiovascular Center, University of Connecticut Health Center
ClinicalTrials.gov Identifier: NCT00760708     History of Changes
Other Study ID Numbers: 02-115-1
Proposal Number 04156012
Award NumberW81XWH-05-1-0060
First Submitted: September 24, 2008
First Posted: September 26, 2008
Last Update Posted: January 17, 2013
Last Verified: January 2013

Keywords provided by Bruce Liang, University of Connecticut Health Center:
nucleosides
neurotransmitter
myocardial ischemia
Adenosine

Additional relevant MeSH terms:
Ischemia
Coronary Disease
Coronary Artery Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Adenosine
Dipyridamole
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Platelet Aggregation Inhibitors